Small Molecule AR Antagonists Overcoming Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for castration-resistant prostate cancer, such as abiraterone and enzalutamide, face limitations due to the development of resistance, particularly driven by truncated and constitutively active androgen receptor variants (AR-Vs) that confer ligand-independent activation, necessitating novel agents targeting the androgen receptor signaling pathway effectively.
Innovation Solution
Development of small molecule agents, including compounds of specific formulas (I, II, III, IV, V, and VII), which inhibit or downregulate androgen receptor signaling by suppressing androgen levels, antagonizing the androgen receptor, or directly targeting AR and AR-Vs, offering alternative therapeutic approaches for prostate cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments such as abiraterone and enzalutamide are used to treat castration-resistant prostate cancer, then initial therapeutic efficacy is achieved, but resistance develops due to truncated and constitutively active androgen receptor variants
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of androgen receptor antagonists to create novel compounds with improved binding affinity and selectivity. The compounds of Formula (I) represent a systematic variation of molecular parameters including substituents at different positions, aiming to overcome resistance mechanisms while maintaining therapeutic efficacy against AR-Vs driven castration-resistant prostate cancer
Solution Approach 2:
The patent segments the androgen receptor signaling pathway into multiple targetable components by designing compounds that can address different resistance mechanisms simultaneously. The molecular structure includes distinct functional regions that can independently interact with various domains of the androgen receptor, enabling multi-modal inhibition of AR signaling
2Productivity
If androgen deprivation therapy is used to treat prostate cancer, then initial disease control is achieved, but castration-resistant prostate cancer develops
Solution Approach 1:
The patent applies preliminary action by designing compounds that proactively target resistance mechanisms before they fully develop. The novel antagonists are structured to prevent the constitutive activation of androgen receptor variants that drive castration resistance, addressing potential resistance pathways in advance rather than waiting for full treatment failure
Solution Approach 2:
The patent introduces intermediary compounds that act as mediators between the therapeutic goal and the biological target. The small molecule antagonists serve as intermediaries that translate the therapeutic intent of androgen deprivation into effective inhibition of androgen receptor signaling, even in the presence of resistance-conferring genetic alterations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These agents demonstrate inhibitory effects on CYP17A1 activity, competitive binding to the androgen receptor, and dose-dependent downregulation of AR and AR-V7, providing clinical benefits by delaying prostate cancer progression and overcoming resistance to existing therapies.
Implementation Method 1
One such approach is to block the biosynthesis of testosterone by inhibiting the enzyme CYP17A1 which is responsible for converting pregnenolone to 17-hydroxypregnenolone and progesterone to 17-hydroxyprogesterone
Implementation Method 2
Another approach is to block the androgen receptor directly using antagonists that competitively bind to AR
Implementation Method 3
The compounds can also function to downregulate AR through suppression of AR transcription or promotion of AR degradation
Data Source
AI summary
The present disclosure relates to androgen receptor signaling inhibitors and the synthesis of the same. Further, the present disclosure teaches the utilization of the androgen receptor signaling inhibitors in a treatment for proliferative diseases, including cancer, particularly prostate cancer, and especially castration-resistant prostate cancer.